JP5405597B2 - Uva/uvb線に対する皮膚の光保護特性を有する光保護組成物、及び美容処理方法 - Google Patents
Uva/uvb線に対する皮膚の光保護特性を有する光保護組成物、及び美容処理方法 Download PDFInfo
- Publication number
- JP5405597B2 JP5405597B2 JP2011546879A JP2011546879A JP5405597B2 JP 5405597 B2 JP5405597 B2 JP 5405597B2 JP 2011546879 A JP2011546879 A JP 2011546879A JP 2011546879 A JP2011546879 A JP 2011546879A JP 5405597 B2 JP5405597 B2 JP 5405597B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- photoprotective
- aeda
- rays
- uvb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003711 photoprotective effect Effects 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 7
- 239000002537 cosmetic Substances 0.000 title claims 2
- 230000005855 radiation Effects 0.000 title description 21
- 239000006286 aqueous extract Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- -1 polyphenol compound Chemical class 0.000 claims 1
- 239000001301 oxygen Substances 0.000 description 34
- 229910052760 oxygen Inorganic materials 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 33
- 206010015150 Erythema Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- 231100000321 erythema Toxicity 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 17
- 230000003078 antioxidant effect Effects 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 11
- 229940114124 ferulic acid Drugs 0.000 description 11
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 11
- 235000001785 ferulic acid Nutrition 0.000 description 11
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000744363 Deschampsia Species 0.000 description 7
- 230000037338 UVA radiation Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960003903 oxygen Drugs 0.000 description 6
- 241000060091 Deschampsia antarctica Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001720 action spectrum Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 231100000589 photocarcinogenesis Toxicity 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000000886 photobiology Effects 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- NHQYRFJWWKBHIO-WGCWOXMQSA-N ethanol (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid Chemical compound CCO.COC1=CC(\C=C\C(O)=O)=CC=C1O NHQYRFJWWKBHIO-WGCWOXMQSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical group 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000019935 photoinhibition Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
ii) 他方では、最も重要な皮膚のクロモフォレと、それとは異なる機構を用いるDAの両方のメラニンが過度の放射エネルギーを排除することができることが重要である。メラニンの場合、過度の放射エネルギーが小さな熱パルスの形態で排除され(「超段階内部変換」)、DAの場合、「光化学抑制」が用いられ、いずれにしろ、生物学的光阻害をブロックすることができることである。
<薄層クロマトグラフィー(TLC)>
TLC技術が、混合物の部分を形成する化合物を分離するために利用された(添付文書1)。得られたAEDAは、以下のような溶剤を使用してシリカゲル60 F254プレート(MERCK)に滴下(spot)された。
●エチルアセテート:メタノール(80対20)
●エチルアセテート:ギ酸:氷酢酸:蒸留水(67対6.4対6.4対18.2)
AEDAに存在するUV吸収特性を有する化合物の吸収性のピークを決定するために、AEDAが200〜400nmのUV/VISのスペクトル分析にかけられた。可視スペクトルが得られるまで、サンプルがエタノールで希釈された状態でSHIMADZU(島津製) UV−160分光光度計が上記目的のために使用された。
<AEDAの抗酸化作用の定量化>
Folinの比色分析試験を行って、AEDAのポリフェノールの量を測定した。この反応は、ヒドロキシル基がベンゼンリングに付着した上記化合物の特性である。Folin−Ciocalteau試薬は、フェノールが存在する場合に黄色から青色に変化した。青色の強度は、765nmの波長の分光光度計によって測定される(添付文書3)。AEDAの抗酸化特性はABTS比色分析法によって評価された。このABTS比色分析法は安定基ABTS+カチオンの連続発生に基づいており、その存在は、734nmの波長(このカチオンが、抗酸化物質との相互作用によって、カチオンの最大吸収ピークの1つとカチオンの変質またはキレート化とを生じさせる波長)においてシステムの吸収性が減少することによって検出される。
<水性AEDAのHPLC基準>
UV検出器によるHPLC分析を実行して、得られたAEDAに存在し得る化合物の基準を得た。HPLCのために、RP−18.5μm 25cmのカラムを有するShimadzu(島津製) SPD−M10AVPダイオードアレイ検出器が使用されており、ここで、メタノール:水の混合物が溶剤として使用されており、サンプルが、0.7〜0.8ml/minの流れ勾配を有するプログラムで動作した。
<Deschampsia Antarcticaの水性抽出物(AEDA)の細胞生存性の調査(細胞サイクル)>
Deschampsia Antarcticaの水性抽出物である(AEDA)の細胞生存性の調査(細胞サイクル)が、HaCaT細胞に紫外線が存在する状態において10mg/mlの投与量で行われた。人間のHaCaTケラチノサイトラインが、10%のウシ胎仔血清を有するDMEM媒体で培養された。
<UVB線下におけるネズミの皮膚に対するDeschampsia Antarcticaの水性抽出物(AEDA)の効果>
a)月曜日から金曜日にかけて、300mg/mlの濃度のDeschampsia Antarcticaを準備して、0.1mlを1日1回投与しつつ、3匹の雄ネズミに対するUVB線の影響を評価するような最初の試験が行われた。中央領域が周辺領域と比較され、その結果、各動物はそれ自体が制御を行っていた。290〜350nmの(広帯域とみなされる)領域において主に313nmで照射を行う、UVC紫外線がフィルタリングされた6*40Wの光源から8cmの部分に動物達を置いた状態で、Zinderと共編者、および他の著者によって示された方法に従って、UVB線(290〜350nm)に曝露した後、形成された紅斑が×印で主観的に評価され、周辺領域(未処理)と中央領域(処理)とを区別して、曝露後に24時間撮影された。結果は以下のようなものであった。
<材料および方法>
20グラムよりも多い重量の40匹の雄ネズミが使用された。40匹の雄ネズミは、収容した後に7日間試験が行われた位置に順応させられた。動物達は、制御温度が22℃であり、相対湿度が50%〜75%であり、新鮮な空気が約10時間毎に取り入れられ、そして12時間毎に明るくなり、暗くなる(7:00から19:00までが明るくなり、19:00から7:00までが暗くなる)サイクルの部屋に置かれた。この期間中およびその実験期間中に、動物達には、標準的な齧歯類用食餌および水道水が任意量与えられた。
<結果>
i)UVB線に曝露されなかった「ブランクの媒介物」(グループ1)のネズミの皮膚の様子は、完全に正常であり、ピンクがかっており、紅斑なしと示された。正常な皮膚組織は組織準備中に観察され、この皮膚組織は、(きめの細かい)正常な角質層、薄い顆粒層および有棘層からなり、細胞の結合が強く、機能的ケラチノサイトの基底細胞層(基底層)には、完全に規則正しい細胞が支持され、1つの細胞において、表皮と皮膚との間の分離部をはっきりとおよび明らかに区切る深い層がグループ化されている。「日焼けした」という用語の定義に適合する細胞の存在はこれらの準備のいずれにおいても観察されなかった。
a)300mg/mlのAEDAを局所的に塗布することにより、UVB線によって生じた紅斑が効果的に減少される。
b)300mg/mlのAEDAを局所的に塗布することにより、日焼けした細胞の出現が95.11%抑制される。
c)この試験で準備されたDeschampsiaの強度は、0.5%のフェルラ酸によって示された強度よりも僅かに優れている。
d)UV光をブロックするのに必要なDeschampsia Antarcticaの濃度は、フェルラ酸よりも10〜50倍高くしなければならない。
Claims (5)
- ナンキョクコメススキから抽出された水性抽出物を含有する光保護組成物であって、
前記水性抽出物は、100%脱イオン水を用いてナンキョクコメススキの組成成分を抽出することによって調製され、UVA線およびUVB線に対する皮膚の光保護特性を有する光保護組成物。 - 前記水性抽出物は、ポリフェノール化合物を含む請求項1に記載の光保護組成物。
- 300mg/mlの前記水性抽出物を含む請求項1または2に記載の光保護組成物。
- 皮膚塗布用のクリーム、ゲル、オイル、またはローションのいずれかの形態で提供される請求項1乃至3のいずれか一つに記載の光保護組成物。
- 請求項4記載の光保護組成物を、UVA線およびUVB線に対する日焼けを防止するために局所的に皮膚に塗布する美容処理方法(但し、ヒトの疾病を予防又は治療する態様を除く)。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2009/000050 WO2010086464A1 (es) | 2009-01-30 | 2009-01-30 | Agente para la fotoprotección cutánea frente a radiaciones uva-uvb |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012516311A JP2012516311A (ja) | 2012-07-19 |
JP5405597B2 true JP5405597B2 (ja) | 2014-02-05 |
Family
ID=42395117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011546879A Expired - Fee Related JP5405597B2 (ja) | 2009-01-30 | 2009-01-30 | Uva/uvb線に対する皮膚の光保護特性を有する光保護組成物、及び美容処理方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8357407B2 (ja) |
EP (1) | EP2392316A4 (ja) |
JP (1) | JP5405597B2 (ja) |
AU (1) | AU2009339186A1 (ja) |
CA (1) | CA2723787A1 (ja) |
WO (1) | WO2010086464A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011058423A2 (en) * | 2009-11-13 | 2011-05-19 | Avesthagen Limited | Identification and characterization of natural chemical entities by liquid chromatography and mass spectrometry lc-ms/ms and uses thereof |
WO2013084193A2 (en) * | 2011-12-07 | 2013-06-13 | Manuel Gidekel | Aqueous extracts of deschampsia antarctica |
MA45503A (fr) | 2016-06-20 | 2019-04-24 | Cantabria Ind Farmaceutica Sa | Utilisation d'extraits dedeschampsia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717808A (ja) * | 1993-07-06 | 1995-01-20 | Japan Vilene Co Ltd | 抗菌性高分子及びその製造方法、並びに抗菌性高分子を使用した抗菌材及びその製造方法 |
DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
US20100310686A1 (en) * | 2007-11-14 | 2010-12-09 | Uxmal S.A., Chile | Extracts of deschampsia antarctica desv, with antineoplastic activity |
-
2009
- 2009-01-30 US US12/736,727 patent/US8357407B2/en not_active Expired - Fee Related
- 2009-01-30 EP EP09839068.5A patent/EP2392316A4/en not_active Withdrawn
- 2009-01-30 JP JP2011546879A patent/JP5405597B2/ja not_active Expired - Fee Related
- 2009-01-30 AU AU2009339186A patent/AU2009339186A1/en not_active Abandoned
- 2009-01-30 CA CA2723787A patent/CA2723787A1/en not_active Abandoned
- 2009-01-30 WO PCT/ES2009/000050 patent/WO2010086464A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2012516311A (ja) | 2012-07-19 |
US8357407B2 (en) | 2013-01-22 |
CA2723787A1 (en) | 2010-08-05 |
EP2392316A4 (en) | 2013-10-23 |
WO2010086464A8 (es) | 2011-02-17 |
EP2392316A1 (en) | 2011-12-07 |
AU2009339186A1 (en) | 2011-07-07 |
US20110195034A1 (en) | 2011-08-11 |
WO2010086464A1 (es) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moghadamtousi et al. | Annona muricata leaves accelerate wound healing in rats via involvement of Hsp70 and antioxidant defence | |
Ichihashi et al. | Preventive effect of antioxidant on ultraviolet-induced skin cancer in mice | |
Cole et al. | Topical ‘Sydney’propolis protects against UV-radiation-induced inflammation, lipid peroxidation and immune suppression in mouse skin | |
Fonseca et al. | Evaluation of the potential of Brazilian propolis against UV‐induced oxidative stress | |
Avila Acevedo et al. | Photoprotection of Buddleja cordata extract against UVB-induced skin damage in SKH-1 hairless mice | |
Regalado et al. | Repair of UVB-damaged skin by the antioxidant sulphated flavone glycoside thalassiolin B isolated from the marine plant Thalassia testudinum Banks ex König | |
Kang et al. | Beneficial effects of dried pomegranate juice concentrated powder on ultraviolet B-induced skin photoaging in hairless mice | |
AU2017259057B2 (en) | Saxifraga extracts for cosmetic or therapeutic use on the skin | |
CN108697610A (zh) | 西番莲种子提取物和包含其的化妆品、药物或皮肤病学组合物 | |
Chen et al. | Photoprotective effects of Sargassum thunbergii on ultraviolet B-induced mouse L929 fibroblasts and zebrafish | |
JP5405597B2 (ja) | Uva/uvb線に対する皮膚の光保護特性を有する光保護組成物、及び美容処理方法 | |
Sun et al. | Inhibition of persimmon tannin extract on guinea pig skin pigmentation | |
Waditee-Sirisattha et al. | Protective effects of mycosporine-like amino acid-containing emulsions on UV-treated mouse ear tissue from the viewpoints of antioxidation and antiglycation | |
West et al. | Morinda citrifolia Linn.(Rubiaceae) leaf extracts mitigate UVB-induced erythema | |
Nagar et al. | Evaluation of potent phytomedicine for treatment of psoriasis using UV radiation induced psoriasis in rats | |
Deng et al. | Pterostilbene's protective effects against photodamage caused by UVA/UVB irradiation | |
Rougier et al. | Protection of the skin against ultraviolet radiations | |
Hassan | Anti-inflammatory and Anti-proliferative Activity of Coconut Oil against Adverse Effects of UVB on Skin of Albino Mice. | |
Sakura et al. | Differences in the histopathology and cytokine expression pattern between chronological aging and photoaging of hairless mice skin | |
Arollado et al. | Cocos nucifera L. endosperm promotes healing of excised wound in BALB/c mice | |
KR19990056976A (ko) | 녹차 폴리페놀에 의한 광노화 억제작용을 갖는 화장료 또는 약제 조성물 | |
Montero et al. | Damaging effects of UVA, blue light, and infrared radiation: in vitro assessment on a reconstructed full-thickness human skin | |
Astutiningsih et al. | Potential as Photoprotective, Antioxidant and Anti-inflammatory of Flavonoid Isolate from Okra Fruit (Abelmoschus esculentus L.) | |
Putranti et al. | The Role of Achatina Fulica Snail Slime Extract Enzymatic Antioxidants as Photoprotector in Sunburn Model Mice | |
Soetrisno et al. | The administration of topical aloe vera extract reduce the number of sunburn cells and expression of caspase-3 on post UVB-lightexposure epidermis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130903 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131030 |
|
LAPS | Cancellation because of no payment of annual fees |